Spectrum Pharmaceuticals R&D per Employee
The R&D Spending per Employee of Spectrum Pharmaceuticals (SPPI) as of Nov 15, 2026 is 289,061.64 USD. In the previous year, R&D Spending per Employee was 597,924.66 USD — a change of -51.66% (lower).
Get this data via API
Financial Data API
R&D per Employee
289,061.64USD
YoY
-51.66%
Last updated:
The Spectrum Pharmaceuticals R&D per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | R&D per Employee | YoY |
|---|---|---|
| 289,061.64USD | -51.66% | |
| 597,924.66USD | -20.19% | |
| 749,157.53USD | +37.88% | |
| 543,321.92USD | -16.46% | |
| 650,383.56USD | +44.10% | |
| 451,335.62USD | +11.81% | |
| 403,671.23USD | +16.09% | |
| 347,712.33USD | -27.13% | |
| 477,136.99USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Spectrum Pharmaceuticals Stock analysis
Frequently Asked Questions about Spectrum Pharmaceuticals stock
R&D Spending per Employee of Spectrum Pharmaceuticals is 289,061.64 USD in 2022.
R&D Spending per Employee of Spectrum Pharmaceuticals changed from 597,924.66 USD to 289,061.64 USD, representing a -51.66% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D Spending per Employee Spectrum Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.
R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.
R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Spectrum Pharmaceuticals historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Workforce — Spectrum Pharmaceuticals
All Key Metrics — Spectrum Pharmaceuticals
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth